Nanexa’s Long-Acting Injectables, including small molecules, proteins and peptides, enable the customized, controlled release of APIs into the bloodstream – increasing compliance, reducing costs and enabling smarter care.
once weekly, monthly or even less frequently
minimizes side effects
enables depot products of potent drugs
minimizes injection volumes
enables use of less potent APIs
applicable to wide range of APIs
biologics, peptides and proteins
coating protects API from degradation during depot time
subcutaneous or intramuscular administration for systemic exposure
local administration e.g. intratumorally for local effect
By enabling a slower, smother release of API into the bloodstream PharmaShell® reduces the high-concentration peaks which potentially cause severe side effects – so increasing compliance. Poor patient compliance is a major challenge for long-term drug treatment in conditions from oncology to psychiatry.
MULTIPLE MYELOMA – CASE EXAMPLE: NEX-20 is Nanexa’s Long-Acting Injectable formulation of lenalidomide (Revlimid), today’s first-line chemotherapy for MM (Multiple Myeloma), a recurring multi-stage cancer. Patients take Lenalidomide as an oral tablet for 21 days continuously in a 28-day cycle Side effects can be severe – for some patients they can be more disruptive and uncomfortable than their MM symptoms.
NEX-20 would replace w21 consecutive daily doses of lenalidomide with a single monthly injection administered in-clinic. The sustained, controlled release – and expected resulting lack of “peaks” in treatment – could significantly reduce side effects, further increasing compliance.
The higher drug load per dose possible with PharmaShell® (from 80 – 90%) enables minimized injection volumes and longer depot formulations – reducing the number of injections and in-clinic visits required.
NEX-18 is Nanexa’s Long-Acting Injectable formulation of azacitidine (Vidaza) – today’s first-line treatment for MDS (Myelodysplastic Syndrome). In its Phase I study, one monthly injection of NEX-18 will replace the current seven consecutive in-clinic injections per month patients currently require.
PharmaShell® formulation offers new capabilities for crafting new therapies and enables new IP options for drug developers working with substances heading off-patent.